ArticleCancer biology & therapy2018

Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.

Tali Ofir Dovrat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.